natgillin/translations-raw huggingface dataset:
The formulation of claim 1 further comprising a pharmaceutically acceptable carrier, said formulation comprising less than or equal to about 0.2% of degradant BMT-115982 or BMT-089290 A tablet according to claim 1, said tablet having less than about 3% total cobicistat impurities after 8 weeks at 40 ° C and 75% relative humidity or less than about 2% cobicistat impurities at about 12 months when stored at room temperature, when stored at 30°C/75%RH, when stored at 25°C/60%RH or when stored at 25 °C/75%RH. 
Formulacija patentnog zahtjeva 1 koja dodatno sadrži farmaceutski prihvatljiv nosač, navedena formulacija koja sadrži manje od ili jednako oko 0.2% proizvoda razgradnje BMT-115982 ii BMT-089290 Tableta u skladu sa patentnim zahtjevom 1, navedena tableta koja ima manje od oko 3% ukupne nečistoće kobicistata nakon 8 tjedana na 40 * € 1 75% relativne vlažnosti ili manje od oko 2% nečistoće kobicistata u oko 12 mjeseci kada se čuva na sobnoj temperaturi, kada se čuva na 302C/75%RV, kada se čuva na 252C/60%RV ili kada se čuva na 25 *C/75%RV.
A compound represented by the formula (I) or its salt: 
Piridil-triazolopirimidin derivat predstavljen formulom (1) ili njegove soli,
3 b shows that the engraved design in the plate has been transferred into the ink patch with good resolution, which remains substantially unchanged by the filling of the engraving with a polymer. 
Slika 3b prikazuje kako je uzorak ugraviran na ploči prenesen u dobroj rezoluciji na otisak tinte, koja se bitno ne mijenja kada se gravura ispuni polimerom.
The method of claim 3 wherein the carrier is selected from the group consisting of sugars, fermentation solubles, feed grains, corn cob flour, cellulose, and other wood fibers, and whey. 
Postupak sukladno patentnom zahtjevu 3 pri čemu je nosač izabran 1z skupine koju čine šećeri, toplivih tvari za fermentaciju, žitarice za hranu, brašno od kukuruznih klipova, celulozu, i druga vlakna drveta, i sirutku
cycloalkyl, unsubstituted or mono- or bi-substituted independently with halogen or C1-9-alkyl, heterocyclyl, 
cikloalkil, nesupstituiran ili mono- ili bi-supstituiran neovisno s halogen ili C1-9-alkil, heterociklil,
Cortexolone-17a-propionate in crystalline form I according to any one of claims 17 to 18 for use in treating pathologies affecting the urogenital system, the endocrine system, the skin and/or the cutaneous appendages. 
Korteksolon-17a-propionat u kristalnom obliku III u skladu s bilo kojim od patentnih zahtjeva 15 do 18, naznačen time što je namijenjen upotrebi u liječenju patoloških pojava koje pogađaju urogenitalni sustav, endokrini sustav, kožu i/ili derivate kože.
The storage space exhibits a width dimension 111 being a multiple of the width dimension 11 of a returnable item for storage in said upwardly oriented storage, whereby a plurality of returnable items can be accommodated substantially or at least in part side by side in the interior space. 
HR P20190701 T1 koja značajno prelazi najveću dimenziju povratnih artikala, pri čemu mnoštvo vraćenih artikala od kojih svaki ima navedenu najveću dimenziju se može smjestiti jedan uz drugoga u unutrašnjosti skladišnog prostora.
substituted and unsubstituted cycloalkyl; and 
(6) supstituirani i nesupstituirani cikloalkil;
A flexible floating walkway as defined in claim 1 characterised in that the outer floating element comprises propulsion bodies in the form of propellers or a water-jet appliance to pull out and maneuver the walkway up to the ship and back to land again. 
Savitljiva plutajuća staza (10) prema bilo kojem od prethodnih zahtjeva, naznačena time što vanjski plutajući element (602) sadrži pogonska tijela u obliku propelera ili naprave na vodomlazni pogon pomoću kojih se staza (10) razvlači i njome manevrira do broda i natrag do kopna,
A pharmaceutical tablet in accordance with the preceding claims having (a) a cracking force of at least 110 N, preferably 120 N, more preferably 130 N, and even more preferably 140 N, when subjected to an indentation test; (b) a penetration depth to crack distance of at least 1.0 mm, preferably 1.2 mm, more preferably 1.4 mm, and even more preferably 1.6 mm, when subjected to an indentation test; and (c) capable of resisting a work of at least 0.06 J without cracking. 
Farmaceutska tableta prema prethodnim zahtjevima naznačena time da ima (a) silu loma od najmanje 110 N, poželjno 120 N, poželjnije 130 N, te najpoželjnije 140 N, kada je podvrgnuta indentacijskom testu; (b) dubinu prodiranja s razmakom pukotine od najmanje 1.0 mm, poželjno 1.2 mm, poželjnije 1.4 mm, te najpoželjnije 1.6 mm, kada je podvrgnuta indentacijskom testu; te (c) da se može oduprijeti radu od najmanje 0.06 J bez loma. S Temperatura
As shown in Figure 2, and with further reference to Figure 3 (left side), system 10 includes a receiver 30 adapted to accept and receive the end 22 of bottle 20 with opening 26. 
Kako je prikazano na slici 2, i s pozivom na sliku 3 (lijeva strana), sustav 10 obuhvaća nosač 30 koji prihvaća 1 prima kraj 22 boce 20 s otvorom 26.
It could be some sort of optical detector, pressure detector, or some sort of float in bottle 20. 
To može biti neka vrsta optičkog davača, davača tlaka ili neka vrsta plovka u boci 20.
A further embodiment of the present invention relates to compounds of the formula (Ia″), where the compounds of the formula (Ia″) are compounds of the formula (I-T22) 
Spojevi prema zahtjevu 1, naznačeni time da spojevi s formulom (1a") su spojevi s formulom (I-T22) HR P20181296 T1 R
a method for treating and/or preventing pain, comprising administering a pharmacologically effective amount of a compound or a pharmacologically acceptable salt thereof according to any one of (1) to (16) to a mammal; 
Uporaba spoja ili njegove farmakološki prihvatljive soli prema bilo kojem od zahtjeva 1 do 6 za proizvodnju farmaceutskog pripravka za liječenje i/ili prevenciju fibromialgije. hept-3-en-6-iljoctena kiselina; hept-3-en-6-iljoctena kiselina; lo
each R5 is independently selected from the group consisting of: 
svakog R5 se neovisno bira iz skupine koju čine:
A pharmaceutical composition prepared by wet granulation as claimed in claim 20, wherein direct compression grade mannitol is used in the wet granulation process. 
Farmaceutski pripravak dobiven postupkom vlažne granulacije prema zahtjevu 20, naznačen time da je u postupku vlažne granulacije korišten izravno komprimiran čisti manitol.
Use according to article 1, wherein the disease or condition is a gynaecological infection. 
Jedan ili više oligomera mliječne kiseline za uporabu prema patentnom zahtjevu 1, pri čemu je infekcija bakterijska infekcija.
A process according to claim 5, characterised in that, in its uncompressed state, the open-cell foam in said core layer has an average thickness which is at least equal to said average cell size, and which is preferably smaller than twenty times said average cell size, more preferably smaller than ten times said average cell size and most preferably smaller than five times said average cell size. 
Postupak prema zahtjevu 6, naznačen time da staničnootvorena pjenasta tvar u svom ne-stiješnjenom stanju u jezgrenom sloju pokazuje prosječnu debljinu, koja je najmanje istovjetna prosječnoj veličini stanica, ali je manja za 20-struko od prosječne veličine stanica.
An apparatus as claimed in any preceding claim, wherein the guide member incorporates leads and/or a driveshaft for the imaging device. 
Aparat prema bilo kojem od prethodnih zahtjeva, pri čemu vodeći element obuhvaća vodove i/ili pogonsko vratilo uređaja za snimanje.
Resin efficiency refers to the ability of the chromatography matrix to elute components in distinct, rather than broad, peaks. 
Efikasnost smole odnosi se na sposobnost kromatografskog matriksa da eluira komponentne u dobro odvojenim i uskim, a ne širokim, peak-ovima.
in the surveillance tool: a step of connecting to the onboard sentinel by wire or wireless means; 
- korak spajanja (EMO) na montirano kućište (10) pomoću žičanih ili bežičnih sredstava;
The pharmaceutical composition for use according to claim 1, wherein the amount of 2,4,6-trifluoro-N-[6-(1-methyl-piperidin-4-ylcarbonyl)-pyridin-2-yl]-benzamide is 50 mg per dose, 100 mg per dose, 200 mg per dose, or 400 mg per dose for oral administration. 
Farmaceutski pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačena time što je količina 2,4,6-trifluor-N-[6-(1-metilpiperidin-4-ilkarbonil)piridin-2-il]benzamida 50 mg po dozi, 100 mg po dozi, 200 mg po dozi, ili 400 mg po dozi kod oralne primjene.
In certain such embodiments the composition comprises at least one polyethylene oxide having, based on rheological measurements, an approximate molecular weight of at least 1,000,000 and at least one polyethylene oxide having, based on rheological measurements, an approximate molecular weight of less than 1,000,000, wherein the composition comprises at least about 10% (by wt) or at least about 20% (by wt) of the polyethylene oxide having, based on rheological measurements, an approximate molecular weight of less than 1,000,000. 
(1) najmanje jedan polietilen oksid koji ima, prema reološkim mjerenjima, približnu molekularnu težinu od najmanje 1,000,000; te (2) najmanje jedno aktivno sredstvo odabrano od opioidnih analgetika pri čemu je opioidni analgetik hidromorfon hidroklorid 1 oblik doziranja sadrži od 1 mg do oko 100 mg hidromorfon hidroklorida; te naznačen time da pripravak sadrži najmanje oko 80 % (težinski) polietilen oksida koji ima, na osnovu reoloških mjerenja, prosječnu molekularnu težinu od najmanje 1,000,000.
Advantageously, amylase is added to the texturized food product after the extruder cooking step but before the additional high pressure cooking. This enhances sensory properties of the product. 
Postupak prema zahtjevu 4 ili 5, naznačen time da: da se amilaza dodaje u teksturirani prehrambeni proizvod nakon koraka kuhanja u ekstruderu, ali prije dodatnog kuhanja pod visokim tlakom.
A method of inducing an immune response against CMV in a patient comprising administering to the patient an immunologically effective amount of the composition of any of embodiments 15-17. 
Imunološki efikasna količina kompozicije prema patentnom zahtjevu 2 ili 3 za uporabu u postupku za indukciju imunološkog odgovora protiv CMV kod pacijenta.
Reconstituted embodiments of the present invention can further be diluted if so desired, with this further dilution not being a limitation of the present invention. 
Rekonstituirane varijante predstavljenog izuma mogu biti dodatno razrijeđene ako je to poželjno, s ovim dodatnim razrjeđenjem koje ne predstavlja ograničenje predstavljenog izuma.
B represents an alkylene group having from 1 to 4 carbon atoms, and said alkylene group being unsubstituted or substituted by an oxo group when R3 represents a heterocyclic group; 
B predstavlja alkilensku skupinu s 1 do 4 atoma ugljika, gdje je navedena alkilenska skupina nesupstituirana ili je supstituirana s okso skupinom kada R> predstavlja heterocikličku skupinu;
wherein Y represents Cl or Br and R′ represents hydrogen or a metal ion, and a compound of formula IV 
, gdje Y predstavlja Cl ili Br, a R' predstavlja vodik ili metalni ion, i spojem formule IV
L is tosyl or mesyl; reacting the diastereoisomeric mixture of formula VIIa (S,R+R,R), or alternatively reacting separately the diastereomer VIIa (S,R) and the diastereomer VIIa (R,R) with a base to obtain the corresponding diastereoisomeric mixture of formula VIIIa (S,R+R,R) 
OH pri čemu je L tosil ili mesil; reakciju dijasteroizomerne mješavine formule Vlla (S, R+R, R), ili alternativno reakciju odvojenog dijasteromera VIla (S, R) i dijasteromera VIla (R, R) s bazom, za dobivanje odgovarajuće dijasteroizomerne mješavine formule VIIIa (S, R+R, R) i.
An airborne wind energy converter according to claim 14, wherein the epicyclic gear (3) comprises a ring gear and a sun gear. 
Sustav uređaja vjetroturbine prema patentnom zahtjevu 12, naznačen time što je epiciklički planetarni prijenosnik (3) jednostupanjski ili višestupanjski planetarni prijenosnik.
The forming method according to claim 7, wherein the process air treatment step comprises, at the end of the socket forming time and only during the time for cooling the material of the end of the pipe, activation, after the cooling sub-step, of a sub-step of enriching the process air with pressurised nebulised water which in turn comprises the following steps: 
Postupak oblikovanja prema zahtjevu 9 ili 10, naznačen time da korak obrade zraka za postupak sadrži, nakon pod- koraka hlađenja, aktivaciju pod-koraka obogaćivanja zraka za postupak sa vodom u obliku magle pod tlakom koji se nadalje sastoji od slijedećih koraka:
A composition for use in improving at least one of motivation, calmness, class participation, ability to tolerate stress and sleep patterns in a human having fragile X syndrome, wherein the composition includes at least one GABA(B) agonist. 
Pripravak namijenjen upotrebi u liječenju osobe sa sindromom lomljivog kromosoma X, naznačen time što pripravak sadrži terapijski djelotvornu količinu najmanje jednog agonista Y-aminomaslačne kiseline.
X is hydrogen or CH3. A compound for use according to claim 26 in the treatment of a disease selected from the group consisting of sepsis chronic obstructive pulmonary disorder, (COPD), rheumatoid arthritis, lupus nephritis and multiple sclerosis. 
Spoj za uporabu u skladu s patentnim zahtjevom 26 za liječenje bolesti, naznačen time, da je bolest odabrana iz skupine koju čine sepsa kronične opstruktivne plućne bolesti (KOPB), Reumatski artritis, lupus nefritis i multipla skleroza.
The method of claim 1, wherein a length of the horizontal tube (3) can widely vary, thus varying a size of the radiator without varying functional characteristics thereof. 
Postupak prema zahtjevu 1, naznačen time da dužina horizontalne cijevi (3) može u velikoj mjeri varirati, tako da varira i veličina radijatora bez mijenjanja njegovih funkcionalnih karakteristika.
The method of claim 1, wherein the compound is 
poželjno spoj je Formule (Ig):
The leveling spacer according to claim 1, wherein said knob can be made monolithically of plastic material. 
Umetak za niveliranje prema prethodnim zahtjevima, naznačen time, da navedeni čvor (15) može biti izrađen monolitno od plastičnog materijala.
A method of treating a subject having a Hepatitis 13 virus (HBV) infection, comprising administering to the subject a therapeutically effective amount of the double stranded RNAi agent of claim 1 or 9, thereby treating said subject. 
Dvolančani RNAi agens u skladu s bilo kojim od patentnih zahtjeva 1 do 8 ili farmaceutski pripravak u skladu s patentnim zahtjevom 10, naznačen time, da se upotrebljava u postupku liječenja subjekta koji ima infekciju virusom hepatitisa B (HBV).
The pharmaceutical composition for use as claimed in any of claims 1 to 3, in which the antibody is a monoclonal, chimeric or humanized antibody, or is an antigen-binding fragment of an antibody. 
Farmaceutski pripravak radi primjene sukladno bilo kojem od zahtjeva 1 do 3, pri čemu je protutijelo monoklonalno, kimerno ili humanizirano protutijelo ili fragment koji veže antigen protutijela.
o Pre-incubate for 5-10 minutes at room temperature. 
* - Pre-inkubiraj tijekom 5-10 minuta na sobnoj temperaturi.
The compound of any one of embodiments 18-29, wherein each cycle is independently multiply substituted with groups selected from cyano, halogen, alkyl, branched alkyl, halogenated alkyl, hydroxyl, alkyloxy, amino, alkylamino, dialkylamino, mercaptanyl, alkylmercaptanyl, alkylsulfonyl, aminosulfonyl, alkylaminosulfonyl, alkylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, aryl, arylalkyl, cycle and cycle-alkyl. 
Tvar iz bilo kojeg od patentnih zahtjeva 1-5, ili njena farmaceutski prihvatljiva sol, pri čemu je Bs opcionalno supstituirani aril ili heteroaril odabran iz grupe koja se sastoji od pri čemu je opcionalna supstitucija halo, cijano, C,-C4 alkil, C,-C4 razgranati alkil, halogenirani C,-C4 alkil, hidroksil, Ci-Cg alkoksi, amino ili Ci-Cg alkilamino.
The antibody or functional protein according to any of enbodiments 1-7, wherein said antibody comprises a VH polypeptide sequence having at least 95% sequence identity to at least one of SEQ ID NOs: 99-112 and a VL polypeptide sequence having at least 95% sequence identity to at least one of SEQ ID NOs: 85-98. 
Humano monoklonsko terapeutsko protutijelo anti-ActRIIB ili funkcionalni protein koji obuhvaća njegov dio koji veže antigen, naznačen/o time, da obuhvaća jednu VH-polipeptidnu sekvencu koja ima najmanje 95% identiteta sekvence od barem jedne od SEQ ID NOs: 99-112, i jednu VL-polipeptidnu sekvencu koja ima najmanje 95% identiteta sekvence od barem jedne od SEQ ID NOs: 85-98, pri čemu navedeno protutijelo ili navedeni funkcionalni protein koji obuhvaća njegov dio koji veže antigen, inhibira vezanje miostatina na ActRIIB.
The compositions, pH and osmolarity of the bath and pipette solution are tabulated below. Salt 
Sastav, pH i osmolarnost otopina za pipetu i kupku prikazani su u donjim tablicama. Sol
Examples of substituted ammonium salts include, for instance, those with lower alkylamines such as trimethylamine and triethylamine; hydroxyalkylamines such as 2-hydroxyethylamine, bis-(2-hydroxyethyl)-amine or tri-(2-hydroxyethyl)-amine; cycloalkylamines such as bicyclohexylamine or dibenzylpiperidine, N-benzyl-B-phenethylamine, dehydroabietylamine, N,N'-bisdehydro-abietylamine, glucamine, N-piperazine methylglucamine; bases of the pyridine type such as pyridine, collidine, quinine or quinoline; and salts of basic amino acids such as lysine and arginine. 
Primjeri supstituiranih amonijevih soli uključuju, primjerice, one s nižim alkilaminima, poput trimetilamina i trietilamina; hidroksialkilaminima, poput 2-hidroksietilamina, bis(2-hidroksietiljamina ili tris(2-hidroksietil)amina; cikloalkilaminima, poput bicikloheksilamina ili dibenzilpiperidina, N-benzil-fB-fenetilamina, dehidroabietilamina, N,N'- bisdehidroabietilamina, glukamina, N-piperazinmetilglukamina; bazama piridinskog tipa, poput piridina, kolidina, kinina ili kinolina; te soli bazičnih aminokiselina, poput lizina i arginina.
Preparation of the compound of formula (I) 
Broj objave europskog patenta:
Ladle bottom according to claim 1 or 2, wherein adjacent upper surfaces (10o, 10od; 10od, 10oi; 10 oi, 10or) of the ladle bottom are dimensioned such that the upper surface (10or, 10oi, 10od) being closer to the lower surface (10u) of the ladle bottom, has an overall area being <60% of the surface (10oi, 10od, 10o) arranged on top. 
Dno grabilice prema zahtjevu 1, naznačeno time, da su susjedne gornje površine (10o, 10od, 10oi, 10or) od dna grabilice, tako dimenzionirane, da gornja površina (10or, 10oi, 10od) koja je bliža donjoj površini (10u) od dna grabilice, ima zauzeto ukupno područje koje je
A cloning or expression vector comprising a nucleic acid sequence according to claim 1 . 
Vektor kloniranja ili ekspresije, naznačen time, da obuhvaća jednu 1li više nukleinskih kiselina prema zahtjevu
A sealed container according to claim 12, wherein the modified atmosphere contains increased levels of oxygen or carbon dioxide. 
Posuda prema patentnom zahtjevu 11, pri čemu modifikcirana atmosfera sadrži povećane nivoe kisika ili ugljik dioksida.
A method of treating cancer comprising administering to a mammal having cancer a therapeutically effective amount of the compound of claim 16 wherein the cancer is leukemia. 
Spoj za uporabu u sklađu s patentnim zahtjevom 19, naznačen time što je rak leukemija.
The method of claim 1, wherein the disease is modulated by CSF1R, FLT3, KIT, and/or PDGFRB kinase. 
Tvar za uporabu u skladu s patentnim zahtjevom 20, pri čemu je bolest modulirana pomoću CSFIR, FLT3, KIT i/li PDGFRB kinaze.
The median numbers of lung metastases at day 14 were as follows: 
Srednji brojevi plućnih metastaza na dan 14 bili su kako slijedi:
wherein Q1 represents a phenylene group, thienylene group, pyridazinylene group or pyrimidinylene group, Q2 represents a phenyl group, thienyl group, pyrazolyl group, oxazolyl group, thiazolyl group, 1,2,4-triazolyl group, pyridyl group, pyridazinyl group, pyrimidinyl group, 4,5-dihydrothiazolyl group, pyrrolidinyl group or piperidinyl group each of which may be substituted by a group(s) selected from the group consisting of a halogen atom, hydroxyl group, C1-C4 alkyl group, halogeno C1-C4 alkyl group, C1-C4 alkoxyl group and halogeno C1-C4 alkoxyl group, 
Medicinska oftalmološka otopina za uporabu prema bilo kojem od Zahtjeva 1 do 5 i 8 do 10, gdje Y predstavlja skupinu -Q!'-Q* gdje Q' predstavlja fenilen skupinu ili piridazinilen skupinu, Q* predstavlja fenil skupinu, pirazolil skupinu, tiazolil skupinu, 1,2,4-triazolil skupinu, piridil skupinu, piridazinil skupinu, pirimidinil skupinu ili 4,5-dihidrotiazolil skupinu od kojih svaka može biti supstituirana skupinom/skupinama izabranim iz grupe koju čine atom halogena, C,-Ca alkil skupina i halogeno C;-Cu alkil skupina.
Selective A2A receptor agonists and antagonists have been widely described in pharmacological, behavioural and neuroprotective experiments in rodents and non-human primates (for reviews see: Richardson et al, 1997, Trends Pharmacol. 
Selektivni agonisti A,x-receptora i antagonisti su dobro opisani u farmakološkim, bihevjoralnim i neuroprotektivnim eksperimentima na štakorima i primatima koji nisu ljudi (za recenziju vidjeti: Richardson et al, 1997, Trends Pharmacol.
The composition or combination for use of claim 5, wherein the other agent is an inhibitor of STMN1, preferably an siRNA against STMN1 or a gamboge or a derivative thereof. 
Pripravak ili kombinacija za uporabu prema zahtjevu 5, gdje je drugo sredstvo inhibitor za STMNI, poželjno SIRNA protiv STMNI1 ili gamboge ili njegov derivat.
Such lactose intolerance could make the incorporation of lactose into the rapamycin carbohydrate derivative unsuitable. 
Takva netolerancija laktoze može učiniti ugradnju laktoze u ugljikohidratni derivat rapamicina neprikladnom.
optionally followed by a second oxidation to obtain the following compound: wherein: n is 1 or 2, 
2 Moa i zatim, prema potrebi, drugoj oksidaciji, čime se dobije slijedeći spoj: R*
To this purpose, said control panel is in fact provided with holes 84 for fastening screws (not shown). 
Upravo u tu svrhu na navedenoj kontrolnoj ploči se nalaze otvori 84 za vijke za pričvršćivanje (nije prikazano).
It is also possible to dispense with such cardboard inner shell and to design the inner shell as a plastic container which provides the desired rigidity. 
Omot za pakiranje u skladu s patentnim zahtjevom 15, naznačen time što je pojačani umetak načinjen kao plastični spremnik, za koji je poželjno da je načinjen pomoću lijevanja injektiranjem.
A rotary device for treating molten metal, said device comprising a hollow shaft at one end of which is a rotor, said rotor having:- 
Rotacijski uređaj za tretman istopljenog metala, naznačen time, što se navedeni uređaj sastoji od šupljeg vratila (30) na čijem se jednom kraju nalazi rotor (40), pri čemu navedeni rotor (40) ima:
The aerosol generator may vary in length from about 2 mm to about 60 mm, preferably from about 5 mm to 40 mm, and most preferably from about 20 mm to 35 mm. 
Generator aerosola može varirati po dužini od oko 2 mm do oko 60 mm, poželjno od oko 5 mm do 40 mm, i najpoželjnije od oko 20 mm do 35 mm.
The method of claim 6, wherein the plurality of subsets to be generated are determined using a plurality of non-zero subset flags, and the plurality of subsets are generated by applying the inverse scan pattern to the significant flags, the coefficient signs and the coefficients levels. 
Postupak prema Zahtjevu 6, gdje se podskupovi koje je potrebno generirati određuju korištenjem oznake podskupa različitog od nule koji ukazuje da li podskup sadrži koeficijente različite od nule ili ne, 1 gdje su podskupovi generirani primjenom obrasca inverznog skeniranja na značajne oznake, znakove koeficijenata i razine koeficijenata.